{
  "catalogId": "503c7f67-d435-4e55-ae1f-4e8202e00565",
  "name": "CYRAMZA 10 MG/ML",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "156 19 34510 00",
  "treatmentDescriptions": "Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutations.Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of &#8805; 400 ng/ml and who have been previously treated with sorafenib.",
  "termsOfIssue": "Prescription required",
  "form": "concentrate for solution for infusion",
  "route": "i.v",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "RAMUCIRUMAB/ML",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01XC21",
      "name": "RAMUCIRUMAB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "CYRAMZA 10 MG/ML VIAL 50ML",
      "manufacturer": {
        "name": "אלי לילי",
        "countryOfOrigin": "IL"
      },
      "strength": [
        {
          "value": 50.0,
          "unit": "ml"
        }
      ],
      "quantity": {
        "value": 50.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "24",
      "storageConditions": "",
      "codes": {
        "moh": "7806",
        "yarpa": "47396",
        "pharmasoft": "9933",
        "barcode": "7290008139793"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 8390.262173,
        "retailMargin": 10.0,
        "maxRetailPrice": 9229.28839,
        "maxPriceWithVAT": 10890.55982
      },
      "formulation": ""
    }
  ],
  "metadata": {
    "version": "1.5",
    "lastUpdated": "2025-08-01T18:03:53.211535",
    "tags": [
      "needs_manual_review"
    ],
    "availableApiOptions": [
      {
        "name": "CYRAMZA 10 MG/ML",
        "registration": "156 19 34510 00",
        "form": ""
      }
    ],
    "smartValidation": {
      "extractedFrom": "CYRAMZA 10 MG/ML VIAL 50ML",
      "processedBy": "smart_validation",
      "bestMatchScore": 0.03333333333333333,
      "status": "failed_match"
    }
  }
}